ÕÒÂÛÎÄÍø > ҽҩѧÂÛÎÄ > ÁÙ´²Ò½Ñ§ >

Äò¶¾Ö¢»¼ÕßѪÇå¶ÔСÊó¹ÇËèºìÏµ×æÏ¸°û¼¯ÂäÐγÉÓ°ÏìµÄÑо¿(1)

                       ×÷ÕߣºËïÙ»ÃÀ Áõ¾´Î° ³ÂÏò¶«

¡¾¹Ø¼ü´Ê¡¿  Äò¶¾Ö¢

¡¡¡¡¡¾ÕªÒª¡¿  Ä¿µÄ  ±¾ÎIJÉÓü׻ùÏËÎ¬ËØÏ¸°ûÅàÑøµÄ·½·¨£¬·ÖÎöÄò¶¾Ö¢»¼ÕßѪÇå¶ÔСÊó¹ÇËèºìÏµ×æÏ¸°û¼¯ÂäÐγɵÄÓ°Ï죬³õ²½Ì½ÌÖºìϸ°ûÉú³ÉÒÖÖÆÒò×ӵĴæÔÚ¡£·½·¨  Ñ¡Ôñ12ÀýÄò¶¾Ö¢ÉöÐÔÆ¶ÑªÎ´Í¸Îö»¼ÕßΪÊÔÑé×飬ÁíÑ¡Õý³£½¡¿µÌå¼ìÕß12ÀýΪÕý³£¶ÔÕÕ×飬½«ÊµÑé×é¡¢Õý³£¶ÔÕÕ×éѪÇå·Ö±ðÏ¡Êͳɲ»Í¬ÖÕŨ¶È£¬²ÉÓü׻ùÏËÎ¬ËØÏ¸°ûÅàÑøµÄ·½·¨¶ÔСÊó¹ÇËèϸ°û½øÐÐÅàÑø£¬¶Ô±È²»Í¬Å¨¶ÈѪÇå×éºìϵ¼¯ÂäÐγɵ¥Î»£¨CFU-E£©¡¢ºìϵ±¬Ê½Ðγɵ¥Î»£¨BFU-E£©µÄ¼¯ÂäÊý¡£½á¹û  ÔÚʵÑé×éÖУ¬ÓëѪÇåŨ¶ÈΪ0µÄŨ¶È×éÏà±È£¬Óë¸÷Ũ¶È×éѪÇ干ͬÅàÑøµÄСÊó¹ÇËèCFU-EºÍBFU-EµÄ¼¯ÂäÊý¾ùÃ÷ÏÔ¼õÉÙ£¬ÇÒËæÑªÇåŨ¶ÈµÄÔö¼Ó£¬Ð¡Êó¹ÇËèCFU-EºÍBFU-EµÄ¼¯ÂäÊýÖð½¥¼õÉÙ£¬¸÷Ũ¶È×é¼ä²îÒìÓÐÏÔÖøÐÔ£¨P£¼0.05£©¡£½áÂÛ  Äò¶¾Ö¢»¼ÕßѪÇåÒÖÖÆÐ¡Êó¹ÇËèºìÏµ×æÏ¸°û¼¯ÂäÐγɣ¬Ë滼ÕßѪÇåŨ¶ÈµÄÔö¼Ó£¬ÒÖÖÆ×÷ÓÃÔöÇ¿£¬¾ßÓмÁÁ¿ÒÀÀµÐÔ¡£

¡¡¡¡¡¾¹Ø¼ü´Ê¡¿  Äò¶¾Ö¢£»Æ¶Ñª£»ºìÏµ×æÏ¸°û£»¼¯ÂäÐγɵ¥Î»²â¶¨

¡¡¡¡¡¾Abstract¡¿  Objective  To investigate the existence of the erythropoiesis inhibitors £¨EI£©.Methods  The present study included twelve undialyzed ESRD patients with anemia.The sera from the uremic patients were added to CFU-E and BFU-E culture in the concentrations ranging from 1.25% to 5%.In vitro CFU-E and BFU-E growth in the presence of sera from ESRD patients was compared with in the presence normal human subjects with the use of normal mice bone marrows.Results  The effects of the sera from uremic patients on CFU-E and BFU-E colony growth in concentrations ranging from 1.25% to 5% were investigated to be dose-dependent.The effect increased with the concentrations increasing of the sera£¨P£¼0.05£©.There were not significant inhibitory effect on the CFU-E and BFU-E growth of mice bone marrow in vitro from sera of the normal subjects.Conclusion  The erythropoiesis inhibitors exist in uremic sera which has a dose-dependent inhibitive effects on the growth CFU-E and BFU-E of normal mice bone marrow cells.

¡¡¡¡¡¾Key words¡¿  uremia;anemia;erythroid progenitor cell;colony-forming units assay

¡¡¡¡Æ¶ÑªÊÇÄò¶¾Ö¢³£¼ûµÄ²¢·¢Ö¢Ö®Ò»£¬ÑÏÖØÓ°Ï컼ÕßµÄÉú»îÖÊÁ¿ºÍ¼²²¡µÄÔ¤ºó¡£ºìϸ°ûÉú³ÉËØ£¨EPO£©È±·¦ÊÇÄò¶¾Ö¢Æ¶ÑªµÄÖ÷ÒªÔ­Òò£¬µ«Ó¦ÓÃÈË»ùÒòÖØ×éºìϸ°ûÉú³ÉËØ£¨rHu-EPO£©ÖÎÁÆÈÔÓÐ20%~30%×óÓҵϼÕßÁÆÐ§²»¼Ñ£Û1£Ý¡£Ä¿Ç°µÄÑо¿ÏÔʾ£¬Ò»Ð©Äò¶¾Ö¢»¼ÕßѪEPOŨ¶È²¢²»Ï½µ£¬¶øÊÇÕý³£ÉõÖÁ¸ßÓÚÕý³££¬ÌáʾÉÐÓÐÆäËûÖØÒªÒò×Ó²ÎÓëÉöÐÔÆ¶ÑªµÄ»úÖÆ£Û2£¬3£Ý¡£ÓÐÑо¿±íÃ÷£¬Äò¶¾Ö¢»¼ÕßѪÇåÄÜÒÖÖÆ¹ÇËèºìÏµ×æÏ¸°ûÉú³¤£¬³ä·Ö͸ÎöÔö¼Ó¶¾ËصÄÏû³ý£¬¿É¸ÄÉÆÄò¶¾Ö¢µÄƶѪ¡¢Ìá¸ßrHu-EPOµÄÁÆÐ§£¬ËùÒÔÌá³öÁËÄò¶¾Ö¢Ä³Ð©¶¾ËØ¿ÉÄÜÊǺìϸ°ûÉú³ÉÒÖÖÆÒò×Ó¡£µ«²»Í¬µÄÑо¿Ð¡×é»ñµÃµÄʵÑé½á¹ûÒ²´æÔÚÕùÒé¡£Òò´Ë£¬½üÄêÀ´ÓйØÄò¶¾Ö¢ºìϸ°ûÉú³ÉÒÖÖÆÒò×ÓÊÇ·ñ´æÔÚÓÖÒýÆðѧÕßÃǵĹØ×¢£¬µ«Ä¿Ç°ÈÔûÓдï³É¹²Ê¶¡£±¾ÎÄͨ¹ý¹Û²ìÄò¶¾Ö¢»¼ÕßѪÇå¶ÔСÊó¹ÇËèºìÏµ×æÏ¸°û¼¯ÂäÐγɵÄÓ°Ï죬³õ²½Ì½ÌÖºìϸ°ûÉú³ÉÒÖÖÆÒò×ÓÊÇ·ñ´æÔÚ¡£

¡¡¡¡1  ¶ÔÏóÓë·½·¨

¡¡¡¡1.1  ʵÑé¶ÔÏó  Ñ¡Ôñ12ÀýÄò¶¾Ö¢ÉöÐÔÆ¶ÑªÎ´Í¸Îö»¼ÕßΪʵÑé×飬ԭ·¢²¡ÎªÂýÐÔÉöÑ×8Àý¡¢¸ßѪѹÉö¶¯ÂöÓ²»¯2Àý¡¢ÂýÐÔÉöÓÛÉöÑ×2Àý£¬ÆäÖÐÄÐ5Àý£¬Å®7Àý¡£»¼Õ߯½¾ùÄêÁ䣨50¡À12£©Ë꣬Cr·¶Î§8.2~14.7mg/dl£¬BUN·¶Î§83~135mg/dl¡£ÈëÑ¡²¡Àý¾ùÎÞÂýÐÔÑ×Ö¢£¨C-·´Ó¦µ°°×ˮƽÕý³££©£¬ÎÞѪҺϵͳ¼²²¡»òÖ×Áö£¬ÎÞÌúȱ·¦£¨ÑªÇåÌúµ°°×£¾100ng/ml£©¡£»¼ÕßÔÚʵÑéǰ¾ùÎÞÊäѪʷ£¬Î´Ê¹ÓùýrHu-EPO¡¢Ìú¼Á£¬ÊµÑéǰһ¸öÔÂδʹÓùýACEI¡£ÁíÑ¡Õý³£½¡¿µÌå¼ìÕß12ÀýÉèΪ¶ÔÕÕ×飬ÄÐ6Àý£¬Å®6Àý£¬Æ½¾ùÄêÁ䣨48¡À14£©Ëê¡£

¡¡¡¡1.2  ʵÑé·½·¨

¡¡¡¡1.2.1  ±ê±¾²É¼¯Óë±£´æ  ʵÑé×é¼°¶ÔÕÕ×éÊÜÊÔÕß¾ùÓÚÇ峿¿Õ¸¹³éÈ¡¾²ÂöѪ£¬ÊÒξ²ÖÃ30minºóÀëÐÄ£¬·ÖÀëѪÇ壬56¡æ¼ÓÈÈÃð»î30min£¬-80¡æ±ùÏä±£´æ±¸Óá£

¡¡¡¡1.2.2  СÊó¹ÇËèϸ°ûºìϵ¼¯ÂäÐγɵ¥Î»£¨CFU-E£©¡¢ºìϵ±¬Ê½Ðγɵ¥Î»£¨BFU-E£©µÄÅàÑø  È¡8~10ÖÜBal-cСÊ󣨾ùÓɾüÊÂҽѧ¿ÆÑ§ÔºÊµÑ鶯ÎïÑо¿ËùÌṩ£©¡£Ð¡Êó»÷Í·´¦ËÀ£¬75%¾Æ¾«½þÅÝ20min¡£Á¢¼´ÎÞ¾úÈ¡³öË«²à¹ÇË裬ÓÃIMDMÅàÑøÒº³å³öÈ«²¿¹ÇËèϸ°û£¬Ì¨ÅÎÀ¶È¾É«½øÐÐϸ°û¼ÆÊý£¬²¢ÓÃIMDMÅàÑøÒºµ÷Õûϸ°ûÃܶÈΪ1¡Á105/0.2ml£¨»îϸ°ûÂÊ£¾95%£©¡£

¡¡¡¡1.2.3  ÅàÑøÌåϵºÍÌõ¼þ  2.7%¼×»ùÏËÎ¬ËØ£¬IMDMÅàÑøÒº£¬10-4mol/LÛÏ»ùÒÒ´¼£¬15%СţѪÇ壬3%¹È°±õ£°·£¬EPO£¨2u/0.2ml£©£¬CSF£¨50ng/ml£©£¬IL-3£¨10ng/ml£©¡£½«»ìÔȵÄÌåϵ·Ö±ð¼Óµ½Á½¸ö30mmÅàÑøÃóÖУ¬¼Ó¸Çºó·ÅÈë37¡æ¡¢±¥ºÍʪ¶ÈµÄ5%CO2ÅàÑøÏäÄÚ¡£ÅàÑøµÚ3Ì죬Áª±½°·È¾É«ºóµ¹ÖÃÏÔ΢¾µÏ¼ÆÊýº¬8¸öÒÔÉÏȾɫÑôÐÔµÄϸ°û¼¯ÂäΪCFU-E¡£ÅàÑøµÚ7Ì죬¼ÆÊýº¬50¸öÒÔÉÏȾɫÑôÐÔµÄϸ°û¼¯ÂäΪBFU-E¡£

¡¡¡¡1.2.4  ʵÑé·½·¨  ½«ÊµÑé×é¡¢¶ÔÕÕ×éѪÇå·Ö±ðÓÃIMDMÅàÑøÒºÏ¡ÊͳÉÖÕŨ¶ÈΪ0£¨ÓõÈÁ¿ÅàÑøÒº´úÌæÑªÇ壬×÷ΪÒõÐÔ¶ÔÕÕ£©¡¢1.25%¡¢2.5%¡¢5.0%£¬¹Û²ìÁ½×鲻ͬŨ¶ÈѪÇå¶ÔСÊó¹ÇËèCFU-E¡¢BFU-E¼¯ÂäÉú³¤µÄÓ°Ïì¡£

¡¡¡¡1.3  ͳ¼ÆÑ§·½·¨  ËùÓÐÊý¾Ý¾ùÒÔ¾ùÊý¡À±ê×¼²î£¨¡Às£©±íʾ¡£²ÉÓÃË«ÒòËØ·½²î·ÖÎö£¬×éÄÚÎÞÏÔÖøÐÔ²îÒìÔòÓõ¥ÒòËØ·½²î·ÖÎö¡¢q¼ìÑé½øÐÐÊý¾Ý´¦Àí¡£ÒÔP£¼0.05±íʾÓÐͳ¼ÆÑ§²îÒì¡£Êý¾Ý´¦ÀíÓ¦ÓÃSPSS 11.5ͳ¼ÆÈí¼þ°ü½øÐС£

¡¡¡¡2  ½á¹û

¡¡¡¡2.1  ʵÑé×é¡¢¶ÔÕÕ×éÊÜÊÔÕß²»Í¬Å¨¶ÈѪÇå¶ÔСÊó¹ÇËèCFU-E¼¯ÂäÉú³¤µÄÓ°Ïì  ¼û±í1¡£ÅàÑøµÚ3Ìì¿É¼ûCFU-E¼¯ÂäÉú³¤¡£ÔÚʵÑé×飬ÓëѪÇåŨ¶ÈΪ0µÄŨ¶È×éÏà±È£¬Óë¸÷Ũ¶È×éѪÇ干ͬÅàÑøµÄСÊó¹ÇËèCFU-EµÄ¼¯ÂäÊý¾ùÃ÷ÏÔ¼õÉÙ£¬ÇÒËæÑªÇåŨ¶ÈµÄÔö¼Ó£¬Ð¡Êó¹ÇËèCFU-EµÄ¼¯ÂäÊýÖð½¥¼õÉÙ£¬¸÷Ũ¶È×é¼ä²îÒìÓÐÏÔÖøÐÔ£»ÔÚ¶ÔÕÕ×éÖУ¬ÓëѪÇåŨ¶ÈΪ0µÄŨ¶È×éÏà±È£¬Óë¸÷²»Í¬Å¨¶ÈѪÇ干ͬÅàÑøµÄСÊó¹ÇËèCFU-EµÄ¼¯ÂäÊý²îÒìÎÞÏÔÖøÐÔ¡£

¹²2Ò³: 1 [2] ÏÂÒ»Ò³


Ôи¾µÄÈé·¿±£½¡
»·Á×õ£°·¶ÔСÊóS180ÈâÁöÒÖÁö×÷ÓõÄÁ¿Ð§¹ØÏµ
¹¤É̹ÜÀí | ¹¤¿ÆÂÛÎÄ | ²ÆÎñ¹ÜÀí | ¹ÜÀíѧ | ¹«¹²¹ÜÀí | ²ÆÕþ˰ÊÕ | ֤ȯ½ðÈÚ | »á¼ÆÉó¼Æ | ¼ÆËã»ú | ·¨ÂÉÂÛÎÄ | ҽҩѧ | ººÓïÑÔÎÄѧ
Éç»áÂÛÎÄ | ¹¤¿ÆÂÛÎÄ | Àí¿ÆÂÛÎÄ | ÎÄ»¯ÂÛÎÄ | ÒÕÊõÂÛÎÄ | ÎÄѧÂÛÎÄ | ÕÜѧÂÛÎÄ | ÕþÖÎÂÛÎÄ | Ó¢ÓïÂÛÎÄ | д×÷Ö¸µ¼ | ¼ÆËã»úÓ¦ÓÃ
www.zlunwen.com ÕÒÂÛÎÄÍø ® °æÈ¨ËùÓÐ ÍøÕ¾µØÍ¼